SAN DIEGO--(BUSINESS WIRE)--Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, today announced that positive pharmacokinetic (PK) data from an investigator-initiated pilot study will be available in a poster session presentation at the Digestive Disease Week (DDW) 2009 Annual Meeting in Chicago. The pilot study, supported by a grant from Santarus, assessed PK differences between immediate-release ZEGERID® Powder for Oral Suspension (omeprazole/sodium bicarbonate) 40 mg and delayed-release omeprazole capsules 40 mg in patients with gastroesophageal reflux disease (GERD) associated with gastroparesis (delayed gastric emptying).
